CD274 and cancer: Treatment with anti-PD-1 or anti-PD-L1 antibodies has shown long-lasting antitumor effects in patients with a variety of cancer types, especially in those exhibiting evidence of pre-existing PD-L1 expression (Hui et al., 2017).